A case of adult metastatic xp11 translocation renal cell carcinoma treated successfully with sunitinib

Clinical Genitourinary Cancer

Volumn 7, Issue 3, 2009, Pages

  Choueiri, Toni ^a   Mosquera, Juan Miguel ^a   Hirsch, Michelle ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alveolar soft part sarcoma; MET; TFE3; Vascular endothelial growth factor

Indexed keywords

SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CHROMOSOME TRANSLOCATION; CHROMOSOME XP; CHROMOSOME XP11; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; KIDNEY CARCINOMA; LYMPH NODE BIOPSY; METASTASIS; NEPHRECTOMY; PARAAORTIC LYMPH NODE; RECURRENT CANCER; SKIN MANIFESTATION; TREATMENT OUTCOME; X CHROMOSOME;

EID: 70449087190     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.031     Document Type: Article

References (13)

1. Eble J, Sauter G, Epstein JI, et al. WHO Classification of Tumors: Tumors of the Genitourinary and Male Genital Organs. Lyon: IARC Press; 2004.
2. Mosquera JM, Dal Cin P, Mertz KD, et al. Validation of a TFE3 break-apart FISH assay in Xp11.2 translocation renal cell carcinomas. Mod Pathol 2008; 21:172A.
3. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003; 27:750-761
4. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007; 31:1149-1160
5. Komai Y, Fujiwara M, Fujii Y, et al. Adult xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res 2009; 15:1170-1176
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124 (Pubitemid 46089672)
7. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131
8. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma: preliminary assessment in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 25(suppl):237s (abstract 5010).
9. Lae M, Argani P, Olshen AB, et al. Global gene expression profiles of renal carcinomas with Xp11 translocations (TFE3 gene fusions) suggest a closer relationship to alveolar soft part sarcoma than to adult type renal cell carcinomas. Mod Pathol 2004; 17(suppl 1):163A (abstract 682).
10. Lae M, Saito T, Barr FG, et al. Expression profiling of pediatric sarcomas with chimeric transcription factors: a study of 153 samples. Mod Pathol 2004; 17(suppl 1):330A (abstract 1390).
11. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signalling by transcriptional upregulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007; 67:919-929
12. Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004; 41:267-273
13. Stacchiotti S, Tamborini E, Bertulli R, et al. Response to sunitinib malate (SM) in alveolar soft part sarcoma (ASPS). J Clin Oncol 2008; 26(suppl):576s (abstract 10592).